RAS-driven oncogenesis is supported by downstream antioxidant programs
In our recent study, we demonstrated that oncogenic RAS (rat sarcoma)-mediated transformation and tumorigenesis are supported by transcriptional induction of a crucial antioxidant component, SLC7A11 (solute carrier family 7 member 11), otherwise known as XCT, a gene encoding the cystine/glutamate tr...
Main Authors: | Jonathan K. M. Lim, Gabriel Leprivier, Poul H. Sorensen |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | Molecular & Cellular Oncology |
Online Access: | http://dx.doi.org/10.1080/23723556.2019.1654814 |
Similar Items
-
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
by: Ozge Tatli, et al.
Published: (2021-12-01) -
UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
by: Kaja Kostyrko, et al.
Published: (2023-07-01) -
Role of the microbiota in oncogenesis
by: Z. V. Grigorievskaya, et al.
Published: (2023-05-01) -
Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma
by: Jianbiao Zhou, et al.
Published: (2023-04-01) -
γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation
by: Daley, D, et al.
Published: (2016)